Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Benzinga · 2d ago
Citizens analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $86 price target.